<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04261166</url>
  </required_header>
  <id_info>
    <org_study_id>BOL-PK-ST-02</org_study_id>
    <nct_id>NCT04261166</nct_id>
  </id_info>
  <brief_title>The Aim of This Study is to Evaluate the Safety and PK of BOL-PK-ST-02A, BOL-PK-ST-02 and BOL-PK-ST-02C Drops and a New Sublingual Tablet Formulation of BOL-PK-ST-02F, BOL-PK-ST-02D, BOL-PK-ST-02E</brief_title>
  <official_title>A Phase I Open-label Study to Assess the Single-dose Pharmacokinetics and Safety of Sublingual Administration of Tablets and Medicated Drops</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Breath of Life International Pharma Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Breath of Life International Pharma Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an open-label, single-dose, healthy volunteer phase 1 study after overnight&#xD;
      fasting designed to study the safety and PK of medicated drops and tablet formulation for&#xD;
      sublingual administration.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Anticipated">December 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) profile - Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>Baseline (up to 15 minutes prior to dosing), 10 minutes , 20 minutes, 30 minutes and 45 minutes and 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours,4 hours ,6 hours, 8 hours, 10 hours and 12 hours post dosing</time_frame>
    <description>Blood will be collected for PK testing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) profile - time to reach maximum plasma concentration (Tmax)</measure>
    <time_frame>Baseline (up to 15 minutes prior to dosing), 10 minutes , 20 minutes, 30 minutes and 45 minutes and 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours,4 hours ,6 hours, 8 hours, 10 hours and 12 hours post dosing</time_frame>
    <description>Blood will be collected for PK testing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) profile - apparent terminal exponential half-life (T1/2)</measure>
    <time_frame>Baseline (up to 15 minutes prior to dosing), 10 minutes , 20 minutes, 30 minutes and 45 minutes and 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours,4 hours ,6 hours, 8 hours, 10 hours and 12 hours post dosing</time_frame>
    <description>Blood will be collected for PK testing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) profile - Area Under the Curve (AUC)</measure>
    <time_frame>Baseline (up to 15 minutes prior to dosing), 10 minutes , 20 minutes, 30 minutes and 45 minutes and 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours,4 hours ,6 hours, 8 hours, 10 hours and 12 hours post dosing</time_frame>
    <description>Blood will be collected for PK testing</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>BOL-PK-ST-02F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sublingual tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BOL-PK-ST-02E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sublingual tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B3 is BOL-PK-ST-02D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sublingual tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BOL-PK-ST-02A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drops</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BOL-PK-ST-02C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drops</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BOL-PK-ST-02B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drops</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BOL-PK-ST-02A</intervention_name>
    <description>drops</description>
    <arm_group_label>BOL-PK-ST-02A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BOL-PK-ST-02C</intervention_name>
    <description>drops</description>
    <arm_group_label>BOL-PK-ST-02C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BOL-PK-ST-02B</intervention_name>
    <description>drops</description>
    <arm_group_label>BOL-PK-ST-02B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BOL-PK-ST-02F</intervention_name>
    <description>Sublingual tablets</description>
    <arm_group_label>BOL-PK-ST-02F</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BOL-PK-ST-02E</intervention_name>
    <description>Sublingual tablets</description>
    <arm_group_label>BOL-PK-ST-02E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BOL-PK-ST-02D</intervention_name>
    <description>Sublingual tablets</description>
    <arm_group_label>B3 is BOL-PK-ST-02D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy, male or female, between 18 and 45 years of age (inclusive).&#xD;
&#xD;
          2. Body mass index (BMI) between 20-30 kg/m2 (both inclusive)&#xD;
&#xD;
          3. No recent cannabis usage&#xD;
&#xD;
          4. Normal rage hepatic functions&#xD;
&#xD;
          5. No electrolytes abnormalities&#xD;
&#xD;
          6. Vital signs at screening (after five minutes resting measured in the supine position)&#xD;
             within the following ranges:&#xD;
&#xD;
               1. Body temperature between 35.0 to 37.5 Â°C&#xD;
&#xD;
               2. Systolic blood pressure, 90 to 150 mmHg*&#xD;
&#xD;
               3. Diastolic blood pressure, 60 to 90 mmHg*&#xD;
&#xD;
               4. Pulse rate, 50 to 90 beats per minute*.&#xD;
&#xD;
               5. *Blood pressure and pulse rate will be taken again in a standing position. After&#xD;
                  two minutes standing, there shall be no more than a 20 mmHg drop in systolic or&#xD;
                  10 mmHg drop in diastolic blood pressure, associated with clinical manifestation&#xD;
                  of postural hypotension).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Blood donation within 90 days&#xD;
&#xD;
          2. History of significant cardiovascular, pulmonary, hepatic, renal, hematologic,&#xD;
             gastroenterology, endocrine, immunology, dermatologic, neurologic or psychiatric&#xD;
             disorders&#xD;
&#xD;
          3. Subjects with a history of alcohol, drug abuse, chronic cannabis use within 2 years of&#xD;
             study&#xD;
&#xD;
          4. Pregnant women&#xD;
&#xD;
          5. Subjects who used any prescription or OTC medication in the past 14 days with the&#xD;
             exception of paracetamol or ibuprofen.&#xD;
&#xD;
          6. Sexually active males whose partner is of childbearing potential who do not agree to&#xD;
             practice two highly effective methods of birth control or remain abstinent during the&#xD;
             study and for three months after the last dose of IMP. Sexually active females of&#xD;
             childbearing potential who do not agree to practice two highly effective methods of&#xD;
             birth control or remain abstinent during the study and for three months after the last&#xD;
             dose of IMP&#xD;
&#xD;
          7. Pregnant, lactating or planning pregnancy during the course of the study and for three&#xD;
             months thereafter.&#xD;
&#xD;
          8. Subjects who had postural drop of &gt; 20 mmHg in systolic blood pressure at screening&#xD;
&#xD;
          9. Patients with heart failure,&#xD;
&#xD;
         10. Subjects with a history of psychotic state in the past or anxiety disorder,&#xD;
&#xD;
         11. Subjects less than 30 y with a history of psychiatric disease in a first-degree family&#xD;
             member.&#xD;
&#xD;
         12. Subjects with a history of addiction or drug abuse&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ziv Medical Center</name>
      <address>
        <city>Zefat</city>
        <zip>13100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shahien Radi, M.D.</last_name>
      <phone>+972508434197</phone>
      <email>shahien.r@iv.health.gov.il</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 4, 2020</study_first_submitted>
  <study_first_submitted_qc>February 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 7, 2020</study_first_posted>
  <last_update_submitted>March 22, 2021</last_update_submitted>
  <last_update_submitted_qc>March 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

